Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) (TA353)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 August 2015
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (TA673)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 February 2021
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA784)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 April 2022
Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA962)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 March 2024
Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy (TA908)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 July 2023
Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer (TA946)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 January 2024
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (TA1055)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 April 2025
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA1007)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 September 2024